Does the media favor EXEL or CLDX?

In the previous week, Exelixis had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Exelixis and 3 mentions for Celldex Therapeutics. Exelixis' average media sentiment score of 1.06 beat Celldex Therapeutics' score of 0.90 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLDX or BMRN?

In the previous week, BioMarin Pharmaceutical had 32 more articles in the media than Celldex Therapeutics. MarketBeat recorded 35 mentions for BioMarin Pharmaceutical and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.74 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 13 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARWR or CLDX?

In the previous week, Arrowhead Pharmaceuticals had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat Arrowhead Pharmaceuticals' score of 0.65 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLDX or MDGL?

In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat Madrigal Pharmaceuticals' score of 0.78 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor HALO or CLDX?

In the previous week, Halozyme Therapeutics had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 3 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.96 beat Celldex Therapeutics' score of 0.90 indicating that Halozyme Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Halozyme Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Celldex Therapeutics (CLDX) Competitors

$40.38 +0.44 (+1.10%)

As of 04:00 PM Eastern

Compare

CLDX vs. EXEL, BMRN, ARWR, MDGL, and HALO

Should you buy Celldex Therapeutics stock or one of its competitors? Celldex Therapeutics's main competitors and comparable companies include Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Exelixis has a net margin of 35.33% compared to Celldex Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Exelixis has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

In the previous week, Exelixis had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Exelixis and 3 mentions for Celldex Therapeutics. Exelixis' average media sentiment score of 1.06 beat Celldex Therapeutics' score of 0.90 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis presently has a consensus price target of $50.07, suggesting a potential downside of 7.42%. Celldex Therapeutics has a consensus price target of $56.08, suggesting a potential upside of 38.89%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Exelixis beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to BioMarin Pharmaceutical?

Celldex Therapeutics (NASDAQ:CLDX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Celldex Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27

Celldex Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Celldex Therapeutics presently has a consensus target price of $56.08, suggesting a potential upside of 38.89%. BioMarin Pharmaceutical has a consensus target price of $88.83, suggesting a potential upside of 33.17%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Celldex Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75

In the previous week, BioMarin Pharmaceutical had 32 more articles in the media than Celldex Therapeutics. MarketBeat recorded 35 mentions for BioMarin Pharmaceutical and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.74 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	13 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Celldex Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Celldex Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Celldex Therapeutics' return on equity of -52.35% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Arrowhead Pharmaceuticals currently has a consensus price target of $97.33, suggesting a potential upside of 11.74%. Celldex Therapeutics has a consensus price target of $56.08, suggesting a potential upside of 38.89%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Arrowhead Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.79	-$1.63M	-$2.25	N/A
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A

In the previous week, Arrowhead Pharmaceuticals had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 12 mentions for Arrowhead Pharmaceuticals and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat Arrowhead Pharmaceuticals' score of 0.65 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Celldex Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Madrigal Pharmaceuticals?

Celldex Therapeutics (NASDAQ:CLDX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Madrigal Pharmaceuticals and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.90 beat Madrigal Pharmaceuticals' score of 0.78 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Madrigal Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics currently has a consensus target price of $56.08, suggesting a potential upside of 38.89%. Madrigal Pharmaceuticals has a consensus target price of $689.93, suggesting a potential upside of 33.52%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Celldex Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, meaning that its stock price is 201% less volatile than the broader market.

Celldex Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A
Madrigal Pharmaceuticals	$958.40M	12.45	-$288.28M	-$12.89	N/A

Celldex Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Celldex Therapeutics' return on equity of -52.35% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

Celldex Therapeutics beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Halozyme Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, meaning that its stock price is 13% less volatile than the broader market.

Halozyme Therapeutics presently has a consensus target price of $91.20, indicating a potential downside of 15.69%. Celldex Therapeutics has a consensus target price of $56.08, indicating a potential upside of 38.89%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Halozyme Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	8.79	$316.89M	$3.35	32.29
Celldex Therapeutics	$1.54M	2,059.12	-$258.76M	-$4.35	N/A

In the previous week, Halozyme Therapeutics had 10 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 3 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 0.96 beat Celldex Therapeutics' score of 0.90 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Halozyme Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 24.86% compared to Celldex Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	24.86%	260.98%	23.91%
Celldex Therapeutics	N/A	-52.35%	-47.61%

Summary

Halozyme Therapeutics beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLDX vs. The Competition

Export

Metric	Celldex Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.14B	$3.99B	$7.28B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	-9.28	11.58	271.52	24.22
Price / Sales	2,059.12	1,370.76	631.45	91.69
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	4.44	17.94	13.44	6.37
Net Income	-$258.76M	-$12.50M	$3.46B	$347.74M
7 Day Performance	-3.74%	3.22%	2.24%	0.08%
1 Month Performance	13.24%	6.53%	5.14%	2.13%
1 Year Performance	83.38%	59.76%	27.85%	20.64%

Celldex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLDX Celldex Therapeutics	2.7375 of 5 stars	$40.38 +1.1%	$56.08 +38.9%	+91.2%	$3.14B	$1.54M	N/A	150
EXEL Exelixis	3.3537 of 5 stars	$52.61 +0.6%	$49.79 -5.4%	+41.8%	$12.95B	$2.44B	16.44	1,077	Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.8185 of 5 stars	$66.97 +0.5%	$88.45 +32.1%	+16.8%	$12.92B	$3.41B	180.46	3,221	Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.058 of 5 stars	$87.87 -0.9%	$97.33 +10.8%	+333.0%	$12.41B	$829.45M	N/A	400	Insider Trade
MDGL Madrigal Pharmaceuticals	3.756 of 5 stars	$526.84 +0.4%	$689.93 +31.0%	+32.5%	$12.19B	$958.40M	N/A	90	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Competitors

CLDX vs. EXEL, BMRN, ARWR, MDGL, and HALO

How does Celldex Therapeutics compare to Exelixis?

Summary

How does Celldex Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Celldex Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Celldex Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Competitors

CLDX vs. EXEL, BMRN, ARWR, MDGL, and HALO

How does Celldex Therapeutics compare to Exelixis?

Is EXEL or CLDX more profitable?

Which has higher valuation & earnings, EXEL or CLDX?

Do institutionals and insiders hold more shares of EXEL or CLDX?

Which has more volatility & risk, EXEL or CLDX?

Does the media favor EXEL or CLDX?

Do analysts rate EXEL or CLDX?

Summary

How does Celldex Therapeutics compare to BioMarin Pharmaceutical?

Is CLDX or BMRN more profitable?

Which has higher valuation & earnings, CLDX or BMRN?

Which has more volatility and risk, CLDX or BMRN?

Do analysts rate CLDX or BMRN?

Does the media prefer CLDX or BMRN?

Do institutionals & insiders hold more shares of CLDX or BMRN?

Summary

How does Celldex Therapeutics compare to Arrowhead Pharmaceuticals?

Is ARWR or CLDX more profitable?

Which has more volatility & risk, ARWR or CLDX?

Do analysts recommend ARWR or CLDX?

Which has better valuation & earnings, ARWR or CLDX?

Does the media refer more to ARWR or CLDX?

Do institutionals and insiders have more ownership in ARWR or CLDX?

Summary

How does Celldex Therapeutics compare to Madrigal Pharmaceuticals?

Do insiders and institutionals have more ownership in CLDX or MDGL?

Does the media prefer CLDX or MDGL?

Do analysts prefer CLDX or MDGL?

Which has more risk & volatility, CLDX or MDGL?

Which has preferable valuation & earnings, CLDX or MDGL?

Is CLDX or MDGL more profitable?

Summary

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Which has more risk & volatility, HALO or CLDX?

Do analysts recommend HALO or CLDX?

Which has higher valuation and earnings, HALO or CLDX?

Does the media favor HALO or CLDX?

Do insiders & institutionals believe in HALO or CLDX?

Is HALO or CLDX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools